Douglas Lane & Associates LLC Has $39.39 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

Douglas Lane & Associates LLC lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 294,787 shares of the life sciences company’s stock after purchasing an additional 4,442 shares during the quarter. Douglas Lane & Associates LLC’s holdings in Illumina were worth $39,392,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ILMN. Versant Capital Management Inc increased its stake in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares in the last quarter. TD Private Client Wealth LLC increased its position in shares of Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after acquiring an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV increased its position in shares of Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after acquiring an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new stake in shares of Illumina in the 2nd quarter worth about $61,000. Finally, Private Trust Co. NA lifted its position in Illumina by 81.2% in the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after acquiring an additional 212 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a report on Thursday, October 17th. Leerink Partners upped their price target on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Barclays raised their price objective on Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. TD Cowen upped their target price on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Finally, Canaccord Genuity Group raised their price target on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research report on Tuesday, November 5th. Eight research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Illumina currently has a consensus rating of “Moderate Buy” and a consensus target price of $165.95.

Illumina Stock Performance

Shares of NASDAQ ILMN traded up $0.12 during trading on Wednesday, reaching $139.20. 643,595 shares of the stock traded hands, compared to its average volume of 1,260,287. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The stock has a market capitalization of $22.08 billion, a P/E ratio of -13.98 and a beta of 1.11. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66. The company has a 50-day moving average of $141.62 and a 200-day moving average of $131.98.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company’s revenue was down 3.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.33 earnings per share. Analysts forecast that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.